Ziel
Over 450 million individuals face depression, with over 800,000 suicide deaths per year, delivering a death rate of one person every 40 seconds. These figures are set to increase as estimates put 1 out of 4 individuals in the future to face similar mental disorders at some stage of life.
NPX-101 is the first product line for treating moderate to severe depression, especially the 30% of patients who are currently drug-resistant. It is a patented non-invasive bioelectronic device that delivers Transcranial Magnetic Stimulation (TMS) in the form of a wearable Magnetic Resonance Imaging (MRI) helmet with shield protection. It delivers more precise and deeper energy stimulation, for fuller more effective therapy, removing the side-effects and other treament discomforts with current day treatment. Phase 1 of the SME instrument fits into the overall company plan of NeuroPrex and Omsbar to reach the market by contributing the financial resources needed to plan a fast sound wider deployment of the NPX-101. It would importantly help to deduce the quickest routes of distribution and market uptake for its entry-point of the U.K.
Wissenschaftliches Gebiet
- medical and health sciencesbasic medicineneurologydementiaalzheimer
- social sciencespsychologypsychotherapy
- medical and health sciencesclinical medicinepsychiatryposttraumatic stress disorder
- engineering and technologymedical engineeringdiagnostic imagingmagnetic resonance imaging
- medical and health sciencesbasic medicineneurologyparkinson
Programm/Programme
- H2020-EU.3.1. - SOCIETAL CHALLENGES - Health, demographic change and well-being Main Programme
- H2020-EU.3.1.4. - Active ageing and self-management of health
- H2020-EU.2.1.1. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Information and Communication Technologies (ICT)
- H2020-EU.2.3.1. - Mainstreaming SME support, especially through a dedicated instrument
- H2020-EU.3.1.6. - Health care provision and integrated care
Thema/Themen
Aufforderung zur Vorschlagseinreichung
Andere Projekte für diesen Aufruf anzeigenUnterauftrag
H2020-SMEINST-1-2016-2017
Finanzierungsplan
SME-1 - SME instrument phase 1Koordinator
SE1 0BL LONDON
Vereinigtes Königreich
Die Organisation definierte sich zum Zeitpunkt der Unterzeichnung der Finanzhilfevereinbarung selbst als KMU (Kleine und mittlere Unternehmen).